These patterns have led many scientists to frame AD as a brain-specific insulin-resistant state , colloquially type 3 diabetes. While not every expert embraces the term, multiple recent reviews detail the mechanistic links
No semaglutide product carries an autoimmune indication
Semaglutide works primarily through GLP-1 receptor pathways to help regulate appetite and blood sugar signaling
Not just chemistry, but biology, precision design, and regulatory depth are now becoming essential to compete in this space." Hari Kiran Chereddi, MD & CEO, HRV Pharma and NHG Pharma GLP-1 Patent Expiry Timeline and Market Dynamics The market opportunity is defined by several critical factors: Patent Expiration: Semaglutide's key patents expire globally by early 2026 Market Growth: Demand for obesity and diabetes treatments growing 12-14% year-over-year Healthcare Savings: Indian companies can save global healthcare systems billions through cost-effective alternatives Regulatory Access: Opportunities to develop biosimilars or complex generics for US and EU markets Beyond Cost Competition: Value-Based Differentiation The competitive landscape for GLP-1 drugs extends beyond traditional cost advantages that have historically defined Indian pharmaceutical success
Future studies incorporating direct measurement of dietary patterns, physical activity levels, and other lifestyle indicators would provide valuable complementary evidence to our findings
Moreover, this approach usually comes with a more manageable zepbound cost with insurance, giving individuals the much-needed financial support to embark on their weight loss journey
